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Abstract: 
To examine the prevalence of consequence stating bias, the selection for publication of a subset of the original 
recorded outcome variables on the basis of the results and its impact on Cochrane reviews. A nine-point 
classification system for missing outcome data in randomized trials was developed and applied to the trials assessed 
in a large, unselected cohort of Cochrane systematic reviews. A sensitivity analysis was undertaken to assess the 
impact of outcome reporting bias on reviews that included a single meta-analysis of the review of primary outcome.  
More than half (157/283 (55%)) the reviews did not include full data for the review primary outcome of interest from 
all eligible trials. The median amount of review outcome data missing for any reason was 10%, whereas 50% or 
more of the potential data were missing in 70 (25%) reviews. It was clear from the publications for 155 (6%) of the 
2486 assessable trials that the researchers had measured and analyzed the review primary outcome but did not 
report or only partially reported the results. For reports that did not mention the review primary outcome, our 
classification regarding the presence of outcome reporting bias was shown to have a sensitivity of 88% (95% CI 
65% to 100%) and specificity of 80% (95% CI 69% to 90%) on the basis of responses from 62 trialists. A third of 
Cochrane reviews (96/283 (34%)) contained at least one trial with high suspicion of outcome reporting bias for the 
review primary outcome. In a sensitivity analysis undertaken for 81 reviews with a single meta-analysis of the 
primary outcome of interest, the treatment effect estimate was reduced by 20% or more in 19 (23%). Of the 42 meta-
analyses with a statistically significant result only, eight (19%) became non-significant after adjustment for outcome 
reporting bias and 11 (26%) would have overestimated the treatment effect by 20% or more.  
Outcome reporting bias is an under-recognized problem that affects the conclusions in a substantial proportion of 
Cochrane reviews. Individuals conducting systematic reviews need to address explicitly the issue of missing outcome 
data for their review to be considered a reliable source of evidence. Extra care is required during data extraction, 
reviewers should identify when a trial reports that an outcome was measured but no results were reported, or events 
observed and contact with trialists should be encouraged. 
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INTRODUCTION: 
Discerning reporting bias in a research is described as 
the choice, based on the effects, of a subset of 
analyses for being revealed. Discerning reporting 
could happen in reference to outcome analyses, 
subgroup analyses, and per method analyses, in the 
place of purpose to deal with analyses, in addition to 
various other analyses. Three categories of discerning 
reporting of results occur: the selective reporting of 
several group of study outcomes, if not all examined 
outcomes are reported; the selective reporting of the 
particular outcome for instance, when an outcome is 
assessed and examined at several time points though 
not all outcomes are reported; and imperfect 
reporting of a selected outcome for instance, when 
the main difference in means around treatments is 
reported to get an outcome but no traditional error is 
provided with.  
 
A particular form of bias as a result of the selective 
reporting of the group of study outcomes is outcome 
reporting bias, that will be defined as the choice for 
release of a part of the authentic recorded outcome 
factors based on the results. Experimental study on 
randomised controlled trials demonstrates intense 
proof of a connection between important results and 
publication: scientific studies that report favorable or 
significant results (P<0.05) are more inclined to be 
published, and results that are statistically important 
have higher chances of being fully reported as 
opposed to those that are not significant (range of 
odds ratios: 2.2 to 4.7).  
 
An evaluation of researches that reviewed experiment 
publications with protocols discovered that 40-62% 
of trials modified, introduced, or overlooked a 
mminimum of primary outcome. The organized 
review process was created to reduce biases and 
random glitches through the review of health care 
interventions. Cochrane systematic reviews are 
globally acknowledged as among the ideal means, if 
not the best source, of dependable updated facts on 
health care. Meta-analysis, a analytical way of  
incorporating is a result of multiple associated but 
separate studies, can generate significant efforts to 
medical research such as, by revealing that there 
surely is explanation to give hope to treatments not 
regularly used or that evidence is missing to support 
treatments which are in wide use. Missing result data 
impacts a methodical review in two ways. 
Publication bias, where research is not released based 
on its results, can cause bias in the analysis of the 
specific outcome in a review, particularly if the 
conclusion to never publish or submit the research 
relates to the results for that outcome.  
 
In a published study that has been identified by the 
reviewer, outcome reporting bias can arise if the 
outcome of interest in the review had been measured 
and analyses but not reported on the basis of the 
results. Little is known about the impact of outcome 
reporting bias on systematic reviews. One previous 
study examined a small cohort of nine Cochrane 
reviews of randomized trials. Although outcome 
reporting bias in the review primary outcome was 
suspected in several individual randomized trials, the 
impact of such bias on the conclusions drawn in the 
meta-analyses was minimal. This study used a very 
select set of reviews, however, and highlighted the 
need for a larger study. In this paper we report the 
findings of the Outcome Reporting Bias in Trials 
(ORBIT) study, in which we applied a new 
classification system for the assessment of selective 
outcome reporting and evaluated the validity of the 
tool. We used the classification system to estimate the 
prevalence of outcome reporting bias and its impact 
on an unselected cohort of Cochrane reviews. To our 
knowledge, this is the first systematic empirical study 
of the impact of outcome reporting bias in 
randomized controlled trials on the results of 
systematic reviews. 
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METHODS: 
We analyzed an unselected cohort of the latest 
feedback from 50 of the 51 Cochrane combination 
review groups released in three issues of the 
Cochrane Library (Issue 4, 2016, Issue 1, 2017, and 
Issue 2, 2017). For every review, a couple of 
investigators (JJK and SD) separately analyzed the 
sorts of outcome strategies segment to find out 
perhaps the review designated a single primary result. 
For people reviews where perhaps no primary 
outcome was comprehensive or numerous primary 
results were designated, the lead reviewer was 
approached and expected to choose a single primary 
outcome from those indexed. When no contact could 
be established or the reviewer(s) could not define a 
single primary outcome, two investigators (PRW and 
SD) independently selected and agreed upon a single 
primary outcome from those listed. 
 
Assessment of systematic reviews: 
A couple of investigators (JJK and SD) inspect all 33 
reviews from Issue 4, 2016 which designated a 
specific primary impact and decided on the 
requirement of additional evaluation of most of but 
two reviews. Both arguments were pertaining to 
perhaps the reasons for exemption were effective of 
outcome revealing bias. Each leftover review was 
read by one researcher (JJK) to confirm whether all 
incorporated tests fully revealed the review main 
result. The reason for exemption about any trial (in 
the attributes of omitted studies section) has also 
been verified for any suggestion of possible result 
reporting bias. As an example, an effort excluded 
since there was no appropriate outcome data involved 
more analysis since the relevant outcome may have 
been assessed but not reported. Any concerns about 
the omitted research were considered PRW. Reviews 
that did not recognize any randomized managed 
studies have not been evaluated further. Likewise, 
reviews have not been assessed additionally if no 
standard concise explanation of the main 
consequence prevails, because outcome reporting 
bias assessment in this situation would be impossible. 
One example is relapse in schizophrenia trials, for 
which definitions include a change in symptom score 
and hospital readmission. 
 
Classification of randomized controlled trials in 
systematic reviews: 
For every review, an end result matrix was created 
revealing the reporting on the primary outcome 
besides other outcomes in each sample incorporated, 
identifying full, partial, or no reporting. An 
illustration of an outcome matrix is provided with in 
table 1. For such an example, “live birth” was the 
review main outcome. The array was accomplished 
making use of the facts through the review and 
modified accordingly in light associated with an 
additional information obtained based on the trial 
reports or through contact with the trialists. 
Outcomes for which the data could be included in a 
meta-analysis were considered to be fully reported. 
Such data may have been in the trial report or may 
have been calculated indirectly from the results. For 
example, the number of events may have been 
calculated from the proportion of events and the 
number of patients in the treatment group, or the 
standard error of the treatment effect may have been 
calculated from the estimate of effect and the 
associated P value.  
 
A classification system was designed to evaluate the 
potential risk of bias when a trial was excluded from 
a meta-analysis, either because the data for the 
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outcome were not reported or because the data were 
reported incompletely (for example, just as “not 
significant”). The system was refined over the initial 
few months of the study, but if an amendment was 
made all previous classifications were reviewed and 
adjusted as appropriate to ensure consistency of 
application. The categories reflect the stages of 
assessing whether an outcome was measured, 
whether an outcome was analysed, and, finally, the 
nature of the results presented (table 2).  
 
 
 
The system identifies whether there is evidence that 
the outcome was measured and analysed but only 
partially reported (A to D classifications), whether 
the outcome was measured but not necessarily 
analysed (E and F), if it is unclear whether the 
outcome was measured (G and H), or if it is clear the 
outcome was not measured (I). A “low risk” 
classification was awarded when it was suspected, 
but not actually known, that the outcome was either 
not measured, measured but not analysed, or 
measured and analysed but either partially reported or 
not reported for a reason unrelated to the results 
obtained. A “no risk” classification was reserved for 
cases where it was known that the outcome was not 
measured, known that it was measured but not 
analysed, or known that it was measured and 
analysed but the reason for partial or no reporting 
was not because the results were statistically non-
significant. For cases where the outcome was 
measured but not necessarily analysed, judgment was 
needed as to whether it was likely (E) or unlikely (F) 
that the measured outcome was analysed and not 
reported because of non-significant results. When it 
was unclear whether the outcome was measured, 
judgment was needed as to whether it was likely that 
the outcome was measured and analysed but not 
reported on the basis of non-significant results (G) or 
unlikely that the outcome was measured at all (H). 
Trials classified as A/D/E/G, C/F/H, and B/I were 
assumed to be at high, low, and no risk of outcome 
reporting bias, respectively, in relation to the review 
primary outcome. Examples of each of the 
classifications in the ORBIT study are shown in web 
table A. 
 
Accuracy and Classification: 
For studies that it was confused whether the analysis 
primary result had even been assessed and/or 
analysed (E, F, G, or H classification; table 2), the 
trialists had been approached through e-mail (address 
taken from either the test report or even a search of 
PubMed or Google) and also asked to verify perhaps 
the review primary result was assessed and analysed. 
If so, the reason behind not reporting the effects was 
requested. Non-responders were approached another 
time if the response had not been obtained within 
three weeks. Trialists were not approached if a 
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reviewer had previously approached them for the 
relevant information.  
 
Two individual sensitivity and specificity 
comparaisons had been performed. The primary 
analysis considered exclusively G and H categories 
and directed to regulate how good our distinction 
system was at judging whether the primary outcome 
of interest in the review had been measured when it 
was not mentioned in the trial report. For this 
analysis only, we incorporated an extra category of G 
classification for trials with binary outcomes where 
we predicted that the outcome was measured but it 
was not reported because there were no events. The 
second analysis compared our classifications with 
information from the trialists to establish whether we 
could predict if biased reporting had occurred. 
Implicitly, E and G classifications suggested that bias 
was likely because it was either clear or assumed that 
the outcome had been measured and possible that 
non-reporting could have been influenced by the non-
significance of the result. These classifications were 
taken to imply bias on the basis of the lack of 
inclusion of non-significant results. The specificity 
was calculated taking F and H classifications to 
indicate no bias. This analysis excluded any studies 
classified as F that were ongoing because it is 
difficult to assess bias until a study is completed. 
Confidence intervals for sensitivity and specificity 
estimates were calculated using standard formulas. 
 
Amount and Impact of Missing Trial Data: 
The amount of missing data per review was 
calculated, firstly on the basis of trials that omitted 
data for any reason and secondly only using those 
trials where data omission was suspected on the basis 
of the results (that is, outcome reporting bias was 
suspected). The maximum bias bound approach was 
used in a sensitivity analysis to estimate the impact of 
outcome reporting bias on the review meta-analysis. 
This approach calculates an upper bound for the bias 
resulting from the number of eligible studies 
suspected of outcome reporting bias, and assumes 
that on average smaller studies (lower precision) will 
have a higher probability of not reporting the 
outcome of interest than larger studies (higher 
precision). This method was applied only to reviews 
that had a single meta-analysis of the review primary 
outcome, because if there were multiple meta-
analyses it would be difficult to ascertain to which 
analyses the trial with suspected outcome reporting 
bias would relate without discussion with a clinical 
expert. The impact was not assessed for trials with H 
or I classifications, where it was suggested that the 
review primary outcome had not been measured, or G 
classifications where the explanation was that there 
were no events. The impact was assessed both in 
terms of the percentage change in the treatment effect 
estimate and the change in the statistical significance 
of the treatment effect estimate after adjustment. 
 
 
RESULTS: 
Assessments of systematic reviews: 
The Cochrane Library exhibited 309 latest reviews in 
Issue 4, 2016, Issue 1, 2017, and Issue 2, 2017 (fig 
1). We omitted 12 feedback by the Cochrane 
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Methodology Review Group. Single major outcomes 
had been designated in 103 feedback, while lead 
evaluators or co-reviewers had been expected to 
choose a single biggest result for the residual 194 
reviews. In 173 cases reviewers were willing to do 
so, with 127 (73%) choosing the first outcome listed. 
For the remaining 21 reviews a single primary 
outcome was selected by the research team (PRW and 
SD). On further examination, nevertheless, 14 
feedback were omitted considering that the review 
main result was not well defined. Among the residual 
283 feedback, the average number of feedback from 
an individual Cochrane overview group was five 
(range 1 to 21, interquartile range (IQR) 2 to 7). The 
five groups with many feedbacks had been the 
hepato-biliary group (21 reviews), the pregnancy and 
childbirth group, the neonatal group, the oral health 
group, and the menstrual issues and subfertility 
group. The average volume of randomised controlled 
studies per review was five (range 0 to 134, IQR 2 to 
10). A total of 126 reviews did not require further 
assessment: 38 did not identify any randomised 
controlled trials and 88 fully reported the primary 
outcome for all eligible trials. This left 157 reviews 
requiring further assessment—that is, 55% (157/283) 
of reviews did not include full data on the primary 
outcome of interest from all eligible trials.  
 
Full reporting of review primary outcomes in 
trials: 
Figure 2 demonstrates a flow diagram for the 
evaluation of the 2562 trials involved in the examine 
cohort of 283 organized reviews. Seventy-six trial 
reports could hardly be evaluated as the content have 
not been in English. Seventy-one per cent 
(1774/2486) of the other studies completely reported 
the review primary result in the trial report. Table 3 
supplies information on 177 trial reports that offered 
complete data on the main outcome of interest that 
was not included in the review. For 59 trials, the data 
were not included in the review for a reason unrelated 
to outcome reporting bias. For 118 trials (7% of the 
1774 trials that fully reported the review primary 
outcome), the review primary outcome data were 
fully reported in the publication but were not 
included in the review. Information on missed 
outcome data was fed back to the reviewers for 
inclusion in a review update. 
 
 
 
 
Classification of trials: 
For 788 (31%) of the 2562 trials included in our 
study, the review primary outcome was either 
partially reported or not reported (fig 2). Seventy-six 
trial reports could not be assessed because the articles 
were not in English, leaving 2486 assessable trials 
and 712 trial reports requiring a classification (545 
included in reviews and 167 excluded from reviews). 
Table 4 shows the classification of these 712 trials. 
For 155 (6%) of the 2486 assessable trials, it was 
clear that the review primary outcome was measured 
and analysed (A, B, C, or D classification), but partial 
reporting meant the data could not be included in a 
meta-analysis. Trials classified as C were grouped 
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according to the nature of the missing data (web table 
B). A total of 359 (50%) of the 712 trials with 
missing data were under high suspicion for outcome 
reporting bias (A, D, E, or G classification; table 4). 
The prevalence of reviews containing at least one 
trial with high outcome reporting bias suspicion was 
34% (96/283). 
 
Accuracy of classification: 
Information on whether the outcome of interest was 
measured and analysed was lacking in 538 trial 
reports (E, F, G, or H classification). Researcher 
found the email addresses of 167 (31%) authors and 
contacted these individuals. Responses were received 
from 65 authors (39%): 26% (9/34) of authors whose 
trial had an E classification; 33% (1/3) who got an F 
classification; 42% (30/71) who got a G 
classification; and 42% (25/59) of individuals from 
trials with an H classification. To determine whether 
the outcome of interest was measured or not, 
researcher compared the assessments against the 
trialists’ information for 55 trials for which the 
outcome had not been mentioned in the trial report (G 
or H classification). The sensitivity for predicting that 
the outcome had been measured was 92% (23/25, 
95% CI 81% to 100%), whereas the specificity for 
predicting that the outcome had not been measured 
was 77% (23/30, 95% CI 62% to 92%; table 5).  
 
To measure this study’s judgment on whether 
outcome reporting bias occurred or not, researcher 
compared the assessments against the trialists’ 
information for 62 trials for which the outcome was 
either clearly measured but not necessarily analysed 
(E and F classification) or had not been mentioned in 
the trial report (G or H classification). Three ongoing 
studies were excluded from this analysis. The 
sensitivity of the classification system for detecting 
bias was calculated to be 88% (7/8, 95% CI 65% to 
100%), whereas the specificity was 80% (43/54, 95% 
CI 69% to 90%; table 7). 
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DISCUSSION: 
Outcome reporting bias was suspected in at least one 
randomised controlled trial in more than a third of the 
systematic reviews we examined (35%), which is 
substantially higher than the number of reviews in 
which a reference to the potential for outcome 
reporting bias was found (7%), thus demonstrating 
under-recognition of the problem. Reseacher has also 
shown through sensitivity analysis that outcome 
report ing bias affects the treatment effect estimate in 
a substantial proportion of Cochrane reviews. 
 
Strengths and limitations of the study: 
The strengths of the study are that researcher 
evaluated a large, unselected cohort of reviews, 
review authors were involved in the assessment of 
outcome reporting bias, and the author of the trial 
included in the reviews was contacted for 
information. In addition, the textual justification for 
each trial classification was checked by a senior 
investigator. Researcher undertooks an internal pilot 
study of 33 reviews to determine the level of 
agreement between two researchers on the need for 
further assessment of a review for suspicion of 
outcome reporting bias. Given that agreement was 
high, researcher concluded that it would be sufficient 
for a single reviewer to assess the remainder of the 
reviews, provided a second reviewer checked the 
reasons for excluded studies where there was 
uncertainty. For the majority of trials that were 
missing outcome data, judgment was needed 
regarding the potential for outcome reporting bias.  
 
CONCLUSION: 
This particular summary, though, depends on the 
presumption which trialists researcher approached 
provided precise facts to us. A past research advised 
that trialists might be hesitant to admit discerning 
reporting. Within this research, the response rate for 
all trialists for whom an e-mail address was received 
was matching in trials which includes a dangerous 
category and those with a low risk category. If 
response bias was functioning, researcher supposed 
the susceptibility of categories to be disregarded 
(because of trialists with high risk classifications 
being less probably to reply when they have precisely 
revealed results) and also uniqueness overestimated 
(due to the trialists with low risk categories being apt 
to respond when they have not selectively reported 
results). With such response bias, the volume of 
selectively reported trials using a review will be 
underestimated; thus understanding outcome stating 
bias on the findings of the reviews studied here might 
have been underestimated. The classifications of 
trials for outcome reporting bias facilitated an 
assessment of the robustness of review conclusions to 
such bias. The maximum bias bound approach was 
the method chosen to examine this source of bias 
because it can be applied to any outcome type. 
Although only 81 (29%) of the 283 reviews studied 
comprised a single meta-analysis of the primary 
outcome of interest and were thus included in the 
assessment, there is no reason to believe the results of 
this assessment would not be generalizable to those 
reviews containing multiple meta-analyses of the 
primary outcome relating to different treatment 
comparisons. However, there is a limitation of study 
such as it has not examined how the impact of 
outcome reporting bias should be assessed in reviews 
that do not include a meta-analysis. 
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